Disclosed Amino Acid Sequence Derived From Bacterium (e.g., Mycoplasma, Anaplasma, Etc.) Patents (Class 424/190.1)
-
Publication number: 20140072592Abstract: The object of the present invention is to provide a method to obtain an antibody for a hydrophobic peptide, which can be used for general purposes easily and with great reliability. Also provided is a method for preparing an antigen characterized in that a hydrophobic peptide, which is unbound to carrier protein, is used as high-molecular-weight aggregates in an aqueous solution containing a nonionic surfactant.Type: ApplicationFiled: January 6, 2012Publication date: March 13, 2014Applicants: SEIKO EPSON CORPORATION, TOAGOSEI CO., LTD.Inventors: Masaji Okamoto, Masato Hanamura, Hitoshi Fukushima, Tetsuhiko Yoshida
-
Publication number: 20140072556Abstract: Disclosed are novel immunogenic proteins derived from Staphylococcus aureus, as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acid encoding the proteins and methods of use of these nucleic acids.Type: ApplicationFiled: April 3, 2012Publication date: March 13, 2014Applicant: Nov Vac APSInventors: Niels Iversen Møller, Andreas Mattsson
-
Patent number: 8669355Abstract: The present invention is concerned with the development of a vaccine against Aeromonas hydrophila for use especially in fish. The invention provides an immunogenic S-layer protein of approximately 50 kDa of A. hydrophila for use in the development of a vaccine, as well as the nucleic acid encoding said protein and vaccines comprising said protein or nucleic acid encoding said protein.Type: GrantFiled: May 14, 2012Date of Patent: March 11, 2014Assignee: University of StirlingInventors: Saravanane Poobalane, Kim Thompson, Alexandra Adams
-
Patent number: 8663655Abstract: The present invention relates to peptides, nucleic acids and methods for transforming a bacterium belonging to the Streptococcus genus by natural competence and their use in the food and feed industry.Type: GrantFiled: June 23, 2010Date of Patent: March 4, 2014Assignee: Dupont Nutrition Biosciences APSInventors: Patrick Boyaval, Christophe Fremaux, Pascal Hols, Laetitia Fontaine, Philippe Horvath
-
Publication number: 20140056967Abstract: The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.Type: ApplicationFiled: August 13, 2013Publication date: February 27, 2014Applicants: GlaxoSmithKline Biologicals S.A., Corixa CorporationInventors: Brenda Barth, India Ajay, Mark Alderson, Jean-Francois L. Maisonneuve, Yves Lobert, Florence Bernadette Nozay, Martine Marchand, Pascal Mettens, Yasir A. Skeiky, Peter Probst
-
Publication number: 20140050757Abstract: The invention provides methods and compositions for the detection and treatment of Anaplasma phagocytophilum and Anaplasma platys infection.Type: ApplicationFiled: November 1, 2013Publication date: February 20, 2014Applicant: IDEXX LABORATORIES, INC.Inventors: Jiayou Liu, Eugene Regis Krah, III, Thomas Patrick O'Connor, JR., Daniel Karl Rieger
-
Publication number: 20140050758Abstract: The present invention provides a process for periplasmic expression of a bacterial toxoid comprising the steps of: a), growing a culture of a gram negative host cell in a fermentation medium, wherein the host cell is transformed with a polynucleotide, and wherein the polynucleotide encodes the bacterial toxoid and a periplasmic signal sequence; or providing a gram negative host cell wherein the host cell is transformed with a polynucleotide, the polynucleotide encodes the bacterial toxoid and a periplasmic signal sequence and wherein the gram negative host cell comprises the bacterial toxoid expressed in the periplasm; a(i)) inducing expression of the bacterial toxoid; b) maturing the host ceil, wherein the maturing step comprises; I) subjecting the host cell to a pH shock; II) incubating the host ceil with no feed addition; and/or III) subjecting the host ceil to a temperature below ?20° C.; and c) extracting the bacterial toxoid from the host cell wherein the extraction process comprises osmotic shock.Type: ApplicationFiled: April 12, 2012Publication date: February 20, 2014Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Philippe Marc Helene Dohottay, Philippe Goffin
-
Publication number: 20140050776Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.Type: ApplicationFiled: May 16, 2013Publication date: February 20, 2014Applicants: INFECTIOUS DISEASE RESEARCH INSTITUTE, GLAXOSMITHKLINE BIOLOGICALS SAInventors: Rhea COLLER, Yves Lobet, Steven Reed
-
Publication number: 20140050756Abstract: The present invention relates to a novel trimeric OprF/I fusion protein comprising a portion of the Pseudomonas aeruginosa outer membrane protein F which is fused with its carboxy terminal end to a portion of the amino terminal end of the Pseudomonas aeruginosa out membrane protein I, wherein said portion of the Pseudomonas aeruginosa outer membrane protein F comprises the amino acids 190-342 of SEQ ID NO: 1 and wherein said portion of the Pseudomonas aeruginosa outer membrane protein I comprises the amino acids 21-83 of SEQ ID NO: 2, and further to a novel Opr F/I fusion protein which contains a disulphide bond pattern, preferably selected from the group consisting of (a) Cys18-Cys27-bond, (b) Cys18-Cys27-bond and Cys33-Cys47-bond, and (c) Cys18-Cys47 and Cys27-Cys33-bond, and to immunogenic variants thereof having at least 85% identity to the amino acid sequence of SEQ ID NO: 3.Type: ApplicationFiled: March 19, 2012Publication date: February 20, 2014Applicant: Valneva Austria GmbHInventor: Robert Schlegl
-
Publication number: 20140044747Abstract: The disclosure relates to a composition comprising two or more immunogenic staphylococcal polypeptides and a multivalent vaccine composition comprising the immunogenic staphylococcal polypeptides.Type: ApplicationFiled: April 11, 2012Publication date: February 13, 2014Applicant: ABSYNTH BIOLOGICS LIMITEDInventors: Jorge Garcia Lara, Simon Foster
-
Patent number: 8647633Abstract: Disclosed herein is a composition comprising a purified fusion protein comprising all or part of F1 antigen of Yersinia pestis fused to the amino terminus of all of V antigen of Yersinia pestis, Yersinia enterocolitica, or Yersinia pseudotuberculosis that is isolated from its expression vector.Type: GrantFiled: May 6, 2008Date of Patent: February 11, 2014Assignee: The United States of America as Represented by the Secretary of the ArmyInventors: David G. Heath, Arthur M. Friedlander, George W. Anderson, Jr., Susan L. Welkos
-
Patent number: 8647634Abstract: A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing E. coli that may produce as an inclusion body a fusion peptide consisting of peptides derived from outer-membrane protein of Avibacterium paragarinarum serotype A and serotype C, step of culturing said E. coli and collecting and purifying inclusion body from culture, and step of preparing a preparation comprising said purified inclusion body, and an avian infectious coryza vaccine comprising as an active ingredient the fusion peptide. A linker sequence may be inserted between the respective peptides comprising the fusion peptide. For the peptide derived from the serotypes A and C, an amino acid sequence region of Region 2 or its vicinity responsible for protection from infection may be used.Type: GrantFiled: December 24, 2009Date of Patent: February 11, 2014Assignee: The Chemo-Sero-Therapeutic Research InstituteInventors: Ryuichi Sakamoto, Susumu Baba, Masashi Sakaguchi, Hiroshi Mizokami
-
Publication number: 20140037670Abstract: The invention is directed to means, based on CyaA-carried polypeptide(s), for use in the immunotherapeutic treatment of first determined pathological condition(s) diagnosed in a mammalian host by eliciting a T cell immune response against a first group of epitopes contained in said polypeptide(s) and in the prophylaxis against second determined pathological condition(s) in the same mammalian host by eliciting a T cell memory immune response against a second group of epitopes contained in said polypeptide(s), said immune responses being obtained after administration of said vector-carried polypeptide(s) into said host, wherein said prophylaxis against second determined pathological condition(s) is not observed when said second group of epitopes is not contained in said administered vector-carried polypeptide(s).Type: ApplicationFiled: January 24, 2012Publication date: February 6, 2014Applicant: GENTICELInventors: Michael EsquerrÉ, Marie Momot, Anne Goubier, Yolande Misseri
-
Publication number: 20140037668Abstract: Compositions comprising a first biological molecule from a Neisseria bacterium and a second biological molecule from a Neisseria bacterium. The term “biological molecule” includes proteins and nucleic acids. Preferred Neisseria species are N. meningitidis and N. gonorrhoeae.Type: ApplicationFiled: June 18, 2013Publication date: February 6, 2014Inventors: Marzia Monica GIULIANI, Mariagrazia PIZZA, Rino RAPPUOLI
-
Publication number: 20140037671Abstract: The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.Type: ApplicationFiled: September 9, 2013Publication date: February 6, 2014Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, SRLInventors: Guido Grandi, John Telford, Giuliano Bensi
-
Publication number: 20140037669Abstract: A number of ?-hemolytic streptococci polynucleotides and polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, are described. Two or more of the polypeptides of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing infection caused by ?-hemolytic streptococci.Type: ApplicationFiled: July 16, 2013Publication date: February 6, 2014Inventors: Ingrid Lea Scully, Annaliesa Sybil Anderson, Michael Hagen, Stephen Bruce Olmsted, Paul Patrick Cleary
-
Patent number: 8642048Abstract: The invention provides a nucleic acid encoding the 37-kDa pneumococcal surface adhesion A protein (PsaA) from Streptococcus pneumoniae. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising unique fragment of at least 10 nucleotides of the 37-kDa protein. Additionally, multiple antigenic peptides that provide protection against S. pneumoniae challenge are provided. These multiple antigen peptides comprise the peptides that immunospecifically bind to the monoclonal antibodies. Also provided are vaccines comprising such immunogenic peptides, and methods of conferring protective immunity against Streptococcus pneumoniae infection by administering therapeutic composition comprising the immunogenic peptides of the invention.Type: GrantFiled: January 27, 2009Date of Patent: February 4, 2014Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Edwin W. Ades, Scott E. Johnson, Danny L. Jue, Jacquelyn S. Sampson, George M. Carlone
-
Patent number: 8642050Abstract: The invention provides proteins from gonococcus (Neisseria gonorrhoeae), including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. They are also useful for distinguishing between gonococcus and meningococcus and, in particular, between gonococcus and serogroup B meningococcus.Type: GrantFiled: February 16, 2009Date of Patent: February 4, 2014Assignee: Novartis AGInventors: Maria Rita Fontana, Mariagrazia Pizza, Vega Masignani, Elisabetta Monaci
-
Publication number: 20140030284Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: July 11, 2013Publication date: January 30, 2014Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.Inventors: P. Noel Barrett, Gerald Aichinger, Brian A. Crowe, Ian Livey, Nina Wressnigg
-
Publication number: 20140030285Abstract: Provided herein are OspA polypeptides from Lyme Disease-causing Borrelia having certain alteration(s). In one embodiment, the alteration(s) increase the conformational stability of the OspA polypeptide containing the alteration(s) while maintaining at least some of the antigenicity of the corresponding unaltered OspA polypeptide. In another embodiment, the altered OspA polypeptide has reduced cross-reactivity to hLFA-1, as compared to the corresponding unaltered OspA polypeptide.Type: ApplicationFiled: July 17, 2013Publication date: January 30, 2014Applicants: Brookhaven Sciences Associates, LLC, Research Foundation of the State University of New York, University of RochesterInventors: Benjamin J. Luft, John J. Dunn, Shohei Koide, Catherine L. Lawson
-
Publication number: 20140030287Abstract: The present invention relates to peptides of the enolase protein from Staphylococcus aureus as well as nucleic acid and nucleic acid sequence homologues encoding the peptides. The present invention also relates to a composition, particularly a S. aureus vaccine, comprising one or more of the enolase peptides described herein or a fragment, derivative or variant thereof capable of generating an immune response that induces a protective antibody response or opsonophagocytic activity of human neutrophils for S. aureus. The present invention also encompasses methods of treating and/or reducing the likelihood of a Staphylococcus infection by administering a composition of the invention.Type: ApplicationFiled: October 3, 2013Publication date: January 30, 2014Inventors: TESSIE B. MCNEELY, LESLIE COPE, SHARON SMITH, AMITA JOSHI, IRENE PAK, ARTHUR FRIDMAN
-
Publication number: 20140030286Abstract: The present invention relates to a peptide capable of forming a covalent complex consisting either of the Jo peptide, a derivative or a fragment thereof, or of the In peptide, a derivative or a fragment thereof. The present invention relates to the various uses thereof.Type: ApplicationFiled: March 26, 2012Publication date: January 30, 2014Inventors: Thierry Vernet, Anne-Marie Di Guilmi
-
Patent number: 8637053Abstract: Chlamydia antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial infection, such as Chlamydia, in a subject.Type: GrantFiled: December 3, 2008Date of Patent: January 28, 2014Assignee: President and Fellows of Harvard CollegeInventors: Darren E. Higgins, Todd Gierahn
-
Patent number: 8637043Abstract: The inventors have discovered that a CK?8-1 truncation variant, CK?8-1 (25-116), is a bifunctional ligand for two distinct GPCRs, chemokine receptor CCR1 and formyl peptide receptor like 1 (FPRL1). Hence, the inventors have discovered that, in addition to its functional activity on CCR1, CK?8-1(25-116) is also a functional ligand for the GPCR receptor FPRL1 that is involved in inflammatory reactions and innate immunity by recruiting monocytes and neutrophils. In addition, the inventors have discovered an alternatively spliced exon of CK?8-1, named SHAAGtide. SHAAGtide, along with its parent chemokine CK?8-1 (25-116), is fully functional on both monocytes and neutrophils that are known to express FPRL1. This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided.Type: GrantFiled: July 5, 2005Date of Patent: January 28, 2014Assignee: Chemocentryx, Inc.Inventors: Thomas J. Schall, Zhenhua Miao, Robert Berahovich, Zheng Wei, Maureen Howard, Brett Premack
-
Patent number: 8637052Abstract: The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from Klebsiella species, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens. Moreover, the present invention provides antibodies binding to such antigen, hybridoma cells producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of inhibiting the interaction activity of such antigen, methods for diagnosis or for treatment or prevention of an infection.Type: GrantFiled: July 6, 2012Date of Patent: January 28, 2014Assignee: Valneva Austria GmbHInventors: Sharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander Von Gabain
-
Publication number: 20140023674Abstract: Compositions and methods are provided for the prevention and treatment of bacterial infections, including pneumococal infections. Compositions provided herein comprise a variety of immunogenic fusion proteins, wherein at least one polypeptide component of a given fusion protein comprises a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. Methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections by employing the various immunogenic fusion proteins having at least one polypeptide component comprising a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof.Type: ApplicationFiled: March 23, 2012Publication date: January 23, 2014Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Elaine Tuomanen, Elizabeth R. Mann
-
Patent number: 8632783Abstract: Staphylococcus aureus Hla polypeptides having various deletions, insertions, and/or mutations which are useful for immunization are provided herein. Also provided herein are Hla heptamers which are non-haemolytic. Additionally, an effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens, including Hla polypeptides having deletions, insertions, and/or mutations, are identified for use in immunization. These polypeptides may optionally be used in combination with S. aureus saccharides.Type: GrantFiled: September 15, 2011Date of Patent: January 21, 2014Assignee: Novartis AGInventors: Fabio Bagnoli, Luigi Fiaschi
-
Patent number: 8632784Abstract: Novel proteins from Streptococcus pneumoniae are described, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.Type: GrantFiled: June 7, 2006Date of Patent: January 21, 2014Assignee: Sanofi Pasteur LimitedInventors: Richard William Falla Le Page, Jeremy Mark Wells, Sean Bosco Hanniffy, Philip Michael Hansbro
-
Publication number: 20140017270Abstract: The present invention relates to a peptide consisting of one antigen of Streptococcus pyogenes (S. pyogenes) of any of the SEQ ID NOS: 1 to 7 or a functional active variant thereof, optionally further consisting of additional amino acid residue(s); a nucleic acid coding for the same; a pharmaceutical composition, especially a vaccine, comprising said peptide or said nucleic acid; an antibody or functional active fragment thereof specifically binding to the antigen; a hybridoma cell line which produces said antibody; a method for producing said antibody; a pharmaceutical composition comprising said antibody; the use of said peptide or said nucleic acid for the manufacture of a medicament for the immunization or treatment of a subject; the use of said antibody or functional fragment thereof for the manufacture of a medicament for the treatment of an infection; a method of diagnosing a S.Type: ApplicationFiled: August 15, 2013Publication date: January 16, 2014Applicant: Intercell Austria AGInventors: Andreas Meinke, Eszter Nagy, Alexander Von Gabain, Manfred Berger, Beatrice Tschanun, Michael Schunn
-
Publication number: 20140017271Abstract: The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from Staphylococcus aureus. The present invention also relates to immunogenic compositions, comprising Staphylococcus aureus capsule polysaccharides conjugated to a carrier protein. In addition, the invention relates to methods of inducing an immune response in subjects against Staphylococcus aureus using immunogenic compositions of the Staphylococcus aureus polypeptides and capsule polysaccharides.Type: ApplicationFiled: September 20, 2013Publication date: January 16, 2014Applicant: Wyeth LLCInventors: Annaliesa Anderson, Viliam Pavliak, Kathrin Ute Jansen, Ingrid Lea Scully, Steven Morris Baker, Jasdeep Singh Nanra, Ellen Murphy, Bruce Arthur Green, Mark Edward Ruppen, Yekaterina Timofeyeva
-
Publication number: 20140010836Abstract: We disclose antigenic polypeptides that induce the production of opsonins, in particular opsonic antibodies, and the use of said antigenic polypeptides in vaccines that are protective against bacterial animal pathogens in particular bacterial pathogens of agriculturally important animal species and companion animals and including zoonotic Gram negative bacterial species.Type: ApplicationFiled: February 7, 2012Publication date: January 9, 2014Applicant: University of SheffieldInventor: Jon Sayers
-
Publication number: 20140010835Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: March 14, 2013Publication date: January 9, 2014Inventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schueler, Benjamin Wizel
-
Patent number: 8623375Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: May 13, 2011Date of Patent: January 7, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger
-
Patent number: 8623383Abstract: The invention relates to the construction of recombinant, immunodominant polypeptides against spotted fever group Rickettsia. The invention also relates to a method for the use of the recombinant proteins, either singly or in combination, in detection and diagnostic assays of spotted fever. The proteins can also be used to induce immune response against spotted fever group Rickettsia.Type: GrantFiled: June 8, 2009Date of Patent: January 7, 2014Assignee: The United States of America as represented by the Secretary of the NavyInventor: Wei-Mei Ching
-
Patent number: 8623376Abstract: The invention relates to the development of chimeric OpsA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: May 13, 2011Date of Patent: January 7, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A., Research Foundation for the State University of New York, Brookhaven Science Associates, LLCInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Patent number: 8623609Abstract: The present invention is directed to proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents.Type: GrantFiled: June 21, 2011Date of Patent: January 7, 2014Assignee: Rutgers, The State University of New JerseyInventor: Maria L. Gennaro
-
Publication number: 20140004140Abstract: This application relates to improved Group B Streptococcus (“GBS”) saccharide-based vaccines comprising combinations of GBS polysaccharides with polypeptide antigens, and vice versa, such that the polypeptide and the saccharide each contribute to the immunological response in a recipient. The combination is particularly advantageous where the saccharide and polypeptide are from different GBS serotypes. The combined antigens may be present as a simple combination where separate saccharide and polypeptide antigens are administered together, or they may be present as a conjugated combination, where the saccharide and polypeptide antigens are covalently linked to each other.Type: ApplicationFiled: September 6, 2013Publication date: January 2, 2014Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Rino Rappuoli, John Telford, Guido Grandi
-
Publication number: 20140004138Abstract: Provided herein are compositions designed to reduce or prevent bacterial infections (for example pneuomococcal infections), nasal carriage, nasal colonization, and central nervous system invasion. Provided herein is a composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO:19 or a variant thereof that can elicit an anti-neuraminidase immune response. Further provided are methods of making and using the compositions disclosed herein. Specifically provided are methods of generating antibodies in a subject comprising administering to the subject an agent or composition taught herein. Also provided are methods of reducing or preventing nasal carriage or pneumococcal infection in a subject comprising administering to the subject a composition taught herein.Type: ApplicationFiled: November 7, 2012Publication date: January 2, 2014Applicant: THE UAB RESEARCH FOUNDATIONInventors: David E. Briles, Susan K. Hollingshead
-
Publication number: 20140004139Abstract: Regions of B. anthracis protective antigen are provided representing sequences recognized by antibodies in subjects that have vaccine induced lethal toxin neutralizing anti-PA IgG responses. The recognition of these PA regions enhances the utility of anti-PA IgG reactivity as an immune correlate of protection against anthrax in a subject and increases predictive probability of survival. Also provided are vaccines that include at least one of these PA regions that when administered to a subject improve the predictive value of vaccine induced anti-PA IgG and TNA responses as immune correlates of protection against inhalation anthrax.Type: ApplicationFiled: August 27, 2013Publication date: January 2, 2014Applicant: Centers for Disease Control and PreventionInventors: Vera A. Semenova, Conrad P. Quinn, Jan Pohl, Pavel Svoboda, Shannon Dalton, Jarad M. Schiffer
-
Patent number: 8617573Abstract: It is disclosed here that synaptotagmin I (syt I) and synaptotagmin II (syt II) are the cellular receptors for botulinum neurotoxin B (BoNT/B) that mediate the cellular entry and toxicity of BoNT/B. The BoNT/B binding domains of syt I and II are also disclosed. While syt I needs gangliosides for BoNT/B binding, syt II can bind to BoNT/B in the absence of gangliosides. Various nucleic acids and polypeptides that relate to the BoNT/B binding domain of syt I or II are disclosed. Further disclosed are methods of reducing BoNT/B toxicity, methods of identifying agents that can block the binding between BoNT/B and syt I or II, methods of identifying agents that can bind to the BoNT/B binding domain of syt I or II, methods of detecting BoNT/B or Clostridium botulinum and kits for use thereof.Type: GrantFiled: October 26, 2011Date of Patent: December 31, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Edwin Raymond Chapman, Min Dong
-
Patent number: 8617574Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen from a nontypable Haemophilus influenzae (H. influenzae) species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a nontypable Haemophilus influenzae species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. More specifically such antigens are produced by or associated with bacterial infections caused by nontypable Haemophilus influenzae.Type: GrantFiled: February 15, 2010Date of Patent: December 31, 2013Assignee: Valneva Austria GmbHInventors: Alexander Von Gabain, Eszter Nagy, Andreas Meinke, Sanja Selak, Markus Hanner, Margarita Smidt, Michaela Weissgram, Birgit Noiges, Stefan Seidel, Julia Bacher, Christina Satke, Wolfgang Schueler, Martin Oleksiewicz
-
Patent number: 8617565Abstract: The present invention relates to a surface exposed protein (protein E; pE), a virulence factor, which can be detected in Haemophilus influenzae, having an amino acid sequence as described in SEQ ID NO 1, an immunogenic fragment of said surface exposed protein, and a recombinant immunogenic protein (pE (A)) or truncated variants thereof based on said surface exposed protein. Nucleic acid sequences, vaccines, plasmids and phages, non human hosts, recombinant nucleic acid sequences, fusion proteins and fusion products are also described. A method of producing the said protein or truncated fragments thereof recombinantly is also disclosed.Type: GrantFiled: January 17, 2007Date of Patent: December 31, 2013Inventors: Arne Forsgren, Kristian Riesbeck
-
Publication number: 20130337003Abstract: The present invention relates to engineered Clostridium difficile type IV pilin (tfp) genes, type IV pilin proteins which can serve as a diagnostic marker for identification of patients infected with C. difficile, and vaccines comprising type IV pilin proteins, antigenic fragments and variants thereof for therapeutic interventions.Type: ApplicationFiled: August 23, 2013Publication date: December 19, 2013Applicant: University of Maryland, BaltimoreInventor: Michael Donnenberg
-
Patent number: 8609106Abstract: Pneumococcal pilus subunit RrgB has at least three clades. Serum raised against a given clade is active against pneumococci which express that RrgB clade, but is not active against strains which express one of the other two clades i.e. there is intra-clade cross-protection, but not inter-clade cross-protection. Thus an immunogenic composition can include at least two different clades of RrgB to improve strain coverage against pilus-containing pneumococci. These multiple clades may be present in the immunogenic composition as separate polypeptides or may be fused as a single polypeptide chain.Type: GrantFiled: June 1, 2010Date of Patent: December 17, 2013Assignee: Novartis AGInventors: Vega Masignani, Michele Anne Barocchi, Monica Moschioni, Paolo Ruggiero
-
Patent number: 8609107Abstract: The invention provides methods of treating subject with polypeptides having at least 80% identity to SEQ ID NO: 5326. The methods stimulate an immune response in the subject and provide methods for prevention and treatment of pathological conditions resulting from bacterial infection.Type: GrantFiled: September 13, 2012Date of Patent: December 17, 2013Assignee: Sanofi Pasteur LimitedInventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
-
Publication number: 20130330369Abstract: The present invention provides a method of tolerizing a subject to botulinum toxin and botulinum toxin variants.Type: ApplicationFiled: October 7, 2011Publication date: December 12, 2013Applicant: Allergan, Inc.Inventors: M. Zouhair Atassi, Behzod Z. Dolimbek, K. Roger Aoki
-
Publication number: 20130330370Abstract: Novel polynucleotide and amino acids of Brachyspira hyodysenteriae are described. These sequences are useful for diagnosis of B. hyodysenteriae disease in animals and as a therapeutic treatment or prophylactic treatment of B. hyodysenteriae disease in animals. These sequences may also be useful for diagnostic and therapeutic and/or prophylactic treatment of diseases in animals caused by other Brachyspira species.Type: ApplicationFiled: June 10, 2013Publication date: December 12, 2013Inventors: David J. Hampson, Tom La, Matthew I. Bellgard, Nyree D. Phillips
-
Publication number: 20130330371Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.Type: ApplicationFiled: August 19, 2013Publication date: December 12, 2013Applicant: WYETH LLCInventors: Annaliesa Sybil Anderson, Maninder K. Sidhu, Robert G. K. Donald, Kathrin Ute Jansen, Narender Kumar Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
-
Publication number: 20130330295Abstract: The disclosure relates to antigenic polypeptides that induce the production of opsonins, in particular opsonic antibodies, and the use of said antigenic polypeptides in vaccines that are protective against human bacterial pathogens.Type: ApplicationFiled: February 7, 2012Publication date: December 12, 2013Inventor: Jon Sayers
-
Patent number: 8603484Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Also described is a method for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 3 polysaccharide covalently linked to a carrier protein, the method including periodic acid oxidation of the polysaccharide in the presence of bivalent cations.Type: GrantFiled: February 4, 2010Date of Patent: December 10, 2013Assignee: Wyeth LLCInventor: A. Krishna Prasad